Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825266 · ClinicalTrials.gov registry record · Phase 2
Insulin Resistance in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00825266: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00825266 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00825266, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in the treatment of those patients found to have insulin resistance.
Interventions
- DRUG Pioglitazone
- DRUG bosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00825266
The ClinicalTrials.gov registry entry for NCT00825266 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00825266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00825266 about?
NCT00825266 is a clinical study titled "Insulin Resistance in Pulmonary Arterial Hypertension". The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in the treatment of those patients found to have insulin resistance.
What is the current status of trial NCT00825266?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00825266?
The interventions under investigation include: Pioglitazone (DRUG), bosentan (DRUG).
Who is sponsoring clinical trial NCT00825266?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.